Evidence-based·Updated November 16, 2026·How we grade evidence

Rivaroxaban

MedicationAnticoagulant (prescription)

Rivaroxaban is a direct oral anticoagulant backed by large trials: it was noninferior to warfarin for stroke prevention in atrial fibrillation with less brain and fatal bleeding, noninferior to standard therapy for treating DVT and PE, and, at a low dose with aspirin, cut major cardiovascular events in stable artery disease at the cost of more bleeding. High-dose vitamin E is the high-severity supplement concern; fish oil, ginkgo and chia are rated low.

Prescription medication: not a dietary supplement

This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.

Quick decision guide

May help most

Adults with atrial fibrillation, DVT or PE, recent hip or knee replacement, or stable coronary or peripheral artery disease whose prescriber recommends rivaroxaban

Common dosing range

Set by your prescriber and depends on the use: for example 20 mg once daily with the evening meal for atrial fibrillation, or 15 mg twice daily with food for 21 days then 20 mg once daily for DVT or PE

When to expect effects

The label notes that the time to onset of its therapeutic effect is short

Watch out for

Boxed warnings: stopping early raises the risk of clots and stroke, and spinal or epidural blood clots can occur with spinal anesthesia or punctures. It can cause serious or fatal bleeding, more so with aspirin, NSAIDs, other blood thinners, SSRIs and SNRIs. Not for people with prosthetic heart valves or triple-positive antiphospholipid syndrome

What is it

Rivaroxaban is a prescription blood thinner (anticoagulant) that directly blocks factor Xa, a clotting protein. It is sold as generic rivaroxaban tablets and as Xarelto tablets and oral suspension. The Xarelto label approves it to lower the risk of stroke in nonvalvular atrial fibrillation, to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) and lower the risk of them coming back, to prevent clots after hip or knee replacement and in acutely ill hospitalized patients, and, together with aspirin, to lower the risk of major cardiovascular events in coronary or peripheral artery disease. It also has approved uses in children.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You have an approved reason for anticoagulation, such as atrial fibrillation, DVT or PE, and your prescriber recommends rivaroxaban
You can take it every day exactly as prescribed, since missed doses quickly lower protection
You are willing to review every supplement and over-the-counter pain reliever with your doctor or pharmacist

Probably skip if…

You have active pathological bleeding or a severe allergic reaction to rivaroxaban (contraindicated)
You have a prosthetic heart valve or triple-positive antiphospholipid syndrome, where the label says it is not recommended
You have moderate or severe liver disease (Child-Pugh B or C) or liver disease that affects clotting
You take a drug the label says to avoid, such as ketoconazole, ritonavir, carbamazepine, phenytoin or rifampin, without your prescriber's review

Evidence at a glance

stroke prevention in atrial fibrillation

Good Evidence
Effect
Similar to warfarin for stroke, with less brain and fatal bleeding
Best fit
Adults with nonvalvular atrial fibrillation at increased stroke risk
Time
Measured as yearly event rates over the trial

treatment of deep vein thrombosis and pulmonary embolism

Good Evidence
Effect
Similar to standard therapy for recurrent clots, with less major bleeding in PE
Best fit
Adults with acute symptomatic DVT or PE
Time
Treatment lasted 3, 6 or 12 months

preventing clots from coming back after initial treatment

Good Evidence
Effect
Large; about 82% fewer recurrent clots than placebo
Best fit
Adults at continued risk of recurrent DVT or PE after at least 6 months of treatment
Time
Measured over 6 to 12 additional months

coronary and peripheral artery disease (with aspirin)

Good Evidence
Effect
Moderate; about 24% fewer major cardiovascular events, with about 70% more major bleeding
Best fit
Adults with stable coronary or peripheral artery disease at low bleeding risk
Time
Measured over a mean of 23 months

Evidence for 4 uses

AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.

stroke prevention in atrial fibrillation

Disease adjunct
Good Evidence

In the double-blind ROCKET AF trial, 14,264 patients with nonvalvular atrial fibrillation at increased stroke risk took rivaroxaban 20 mg a day or dose-adjusted warfarin. Stroke or systemic embolism occurred in 1.7% per year on rivaroxaban versus 2.2% per year on warfarin in the per-protocol analysis (hazard ratio 0.79), meeting noninferiority; in the intention-to-treat analysis it was not superior (2.1% vs 2.4% per year). Major and nonmajor clinically relevant bleeding was similar, but bleeding in the brain (0.5% vs 0.7%) and fatal bleeding (0.2% vs 0.5%) were less common.

Effect size
Similar to warfarin for stroke, with less brain and fatal bleeding
Time to effect
Measured as yearly event rates over the trial
Best fit
Adults with nonvalvular atrial fibrillation at increased stroke risk
Less likely
People with mechanical or prosthetic heart valves, who were not studied and for whom it is not recommended

Bottom line: Rivaroxaban protects against stroke in atrial fibrillation about as well as warfarin, with fewer brain bleeds.

treatment of deep vein thrombosis and pulmonary embolism

Disease adjunct
Good Evidence

Two open-label randomized trials compared rivaroxaban alone (15 mg twice daily for 3 weeks, then 20 mg once daily) with injected enoxaparin followed by warfarin or acenocoumarol. In 3,449 patients with DVT, recurrent clots occurred in 2.1% versus 3.0%, and in 4,832 patients with PE in 2.1% versus 1.8%; both met noninferiority. Major bleeding was lower with rivaroxaban in the PE trial (1.1% vs 2.2%), and the main bleeding outcome was similar in the DVT trial (8.1% in each group).

Effect size
Similar to standard therapy for recurrent clots, with less major bleeding in PE
Time to effect
Treatment lasted 3, 6 or 12 months
Best fit
Adults with acute symptomatic DVT or PE
Less likely
People with PE who are hemodynamically unstable or may need clot-dissolving treatment, for whom the label says not to start it in place of heparin

Bottom line: Rivaroxaban treats DVT and PE as well as the older injection-plus-warfarin approach, as a single pill.

preventing clots from coming back after initial treatment

Disease adjunct
Good Evidence

In a double-blind continued-treatment study, 1,196 patients who had completed 6 to 12 months of treatment for a blood clot took rivaroxaban 20 mg daily or placebo for another 6 or 12 months. Recurrent clots occurred in 1.3% on rivaroxaban versus 7.1% on placebo (hazard ratio 0.18), while nonfatal major bleeding occurred in 0.7% versus none. The label's current dose for this use is 10 mg once daily, which this trial did not test.

Effect size
Large; about 82% fewer recurrent clots than placebo
Time to effect
Measured over 6 to 12 additional months
Best fit
Adults at continued risk of recurrent DVT or PE after at least 6 months of treatment
Less likely
People at high bleeding risk, in whom the extra bleeding may outweigh the benefit

Bottom line: Continuing rivaroxaban after a clot sharply lowers the chance of another, with a small bleeding cost.

coronary and peripheral artery disease (with aspirin)

Disease adjunct
Good Evidence

In the double-blind COMPASS trial of 27,395 people with stable atherosclerotic disease, rivaroxaban 2.5 mg twice daily plus aspirin lowered cardiovascular death, stroke or heart attack compared with aspirin alone (4.1% vs 5.4%; hazard ratio 0.76) over a mean of 23 months, but major bleeding rose (3.1% vs 1.9%). Intracranial and fatal bleeding did not differ significantly. Rivaroxaban 5 mg twice daily alone was not better than aspirin and caused more major bleeding.

Effect size
Moderate; about 24% fewer major cardiovascular events, with about 70% more major bleeding
Time to effect
Measured over a mean of 23 months
Best fit
Adults with stable coronary or peripheral artery disease at low bleeding risk
Less likely
People at high bleeding risk, and anyone considering rivaroxaban alone instead of aspirin

Bottom line: Low-dose rivaroxaban plus aspirin prevents more heart events than aspirin alone, at the price of more bleeding.

How it works

Rivaroxaban binds factor Xa and blocks it, which slows the chain reaction that makes fibrin clots. Unlike warfarin, it does not work through vitamin K, and the label says routine clotting tests such as the INR are not recommended for monitoring it. Its half-life is 5 to 9 hours in healthy younger adults, so missing doses quickly lowers protection. Rivaroxaban is cleared by the enzyme CYP3A4 and the P-gp transporter. Drugs that strongly block both raise its levels and bleeding risk, and drugs that strongly speed up both lower its levels and raise clot risk. For supplements, the main concern is anything that adds to bleeding, such as high-dose vitamin E. A standardized ginkgo extract did not change rivaroxaban levels in healthy adults, and fish oil and chia appear to matter little, although neither has been tested with rivaroxaban itself.

How to take it

1. Typical dose
Your prescriber sets the dose, which depends on the reason and on kidney function. The Xarelto label lists for adults: atrial fibrillation 20 mg once daily with the evening meal (15 mg once daily if creatinine clearance is 50 mL/min or less); DVT or PE treatment 15 mg twice daily with food for the first 21 days, then 20 mg once daily with food; lowering the risk of recurrence after at least 6 months of treatment 10 mg once daily; after hip replacement 10 mg once daily for 35 days, and after knee replacement for 12 days; acutely ill medical patients 10 mg once daily for a total of 31 to 39 days; coronary or peripheral artery disease 2.5 mg twice daily with aspirin 75 to 100 mg once daily.
2. Higher studied dose
The highest labeled adult dose is 15 mg twice daily (30 mg a day) during the first 21 days of DVT or PE treatment. In the COMPASS trial, 5 mg twice daily alone was not better than aspirin and caused more major bleeding.
3. Timing
At the same time each day. For a missed dose, the label says: on 15 mg twice daily, take it right away so the day's total is 30 mg (two 15 mg tablets may be taken at once); on once-daily dosing, take the missed dose right away, but never take two doses in the same day to make up for it; on 2.5 mg twice daily, skip it and take the next dose on schedule.
4. With food
The 15 mg and 20 mg tablets are taken with food (the evening meal for atrial fibrillation). The 2.5 mg and 10 mg tablets can be taken with or without food. If you cannot swallow tablets, the label says they can be crushed and mixed with applesauce, and a crushed 15 mg or 20 mg tablet should be followed right away by food.
5. Split dosing
Twice-daily dosing applies only to the first 21 days of DVT or PE treatment and to the 2.5 mg dose for artery disease.
6. How long to try
Your prescriber decides. Do not stop on your own: the boxed warning says stopping early raises the risk of clots and stroke. Before surgery or procedures, your prescriber or surgeon plans when to pause and restart it.

What to track

Unusual bruising, nosebleeds, bleeding gums, pink or brown urine, red or black stools, coughing or vomiting blood, or heavy periods (contact your provider promptly)
Severe headache, weakness, dizziness or fainting, which can signal internal bleeding (seek emergency care)
Back pain, numbness, tingling or leg weakness after spinal anesthesia or a spinal tap (seek emergency care)
Every new medicine or supplement, especially pain relievers, antidepressants and herbal products
Kidney function tests as your prescriber schedules them

Bottom line: Your prescriber sets the dose; take it daily as directed (15 and 20 mg with food), never stop on your own, and check every supplement for bleeding risk.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

Bleeding, the most common side effect in adults (over 5%), from bruising and nosebleeds to more serious bleedingBack pain, belly pain and muscle spasmDizziness, tiredness and trouble sleepingItching

Serious risks

Who should avoid it

Pregnancy & breastfeeding

Pregnancy: the Xarelto label says the limited data in pregnant women are not enough to determine a drug-associated risk of birth defects or miscarriage, that rivaroxaban crossed the human placenta in a laboratory model, and that it should be used with caution because of the potential for pregnancy-related bleeding and emergency delivery; its effect cannot be reliably monitored with standard lab tests and dosing in pregnancy has not been studied. Anyone who could become pregnant should discuss pregnancy planning with their doctor. Breastfeeding: rivaroxaban has been found in human milk, and there are not enough data on its effects on the breastfed child or on milk production; the label says to weigh the benefits of breastfeeding against the mother's need for treatment.

Interactions

Vitamin E (high-dose supplements)High

High-dose vitamin E can make platelets less sticky and may add to the bleeding risk of blood thinners. In an observational study of 566 people with atrial fibrillation taking warfarin-type blood thinners, those with higher blood vitamin E levels had more bleeding; the authors said further study is needed to see whether this holds for newer anticoagulants such as rivaroxaban. Do not start high-dose vitamin E without asking your prescriber; vitamin E from food is not the concern.

Ketoconazole, ritonavir and other drugs that strongly block both CYP3A and P-gpHigh

The label says to avoid these combinations because they raise rivaroxaban levels and may increase bleeding risk. People with reduced kidney function should also not take it with combined P-gp and moderate CYP3A blockers such as erythromycin unless the benefit justifies the risk. Make sure every prescriber knows you take rivaroxaban.

Carbamazepine, phenytoin, rifampin and other strong CYP3A and P-gp inducersHigh

The label says to avoid these combinations because they lower rivaroxaban levels and may increase the risk of clots and stroke. Ask your prescriber before starting any of them.

Aspirin, NSAIDs (ibuprofen, naproxen), clopidogrel, other blood thinners, SSRIs and SNRIsHigh

The label says these increase bleeding risk with rivaroxaban and to avoid other anticoagulants unless the benefit outweighs the risk. Aspirin is part of the prescribed regimen for coronary and peripheral artery disease, but ask your pharmacist before using any over-the-counter pain reliever.

St. John's wortHigh

The Xarelto label says to avoid St. John's wort, which it names among the combined P-gp and strong CYP3A inducers that lower rivaroxaban levels and may increase the risk of clots and stroke. In two studies of 12 healthy volunteers each, St. John's wort lowered rivaroxaban exposure by 24% and 25%, and in one its anti-clotting effect fell by 20%. Do not stop rivaroxaban; tell your prescriber if you take the herb, whose enzyme effect took about a week to wear off after stopping in one study.

Fish oil (omega-3)Low

Omega-3 fats have a mild effect on platelets, so in theory they add to an anticoagulant. In a randomized trial of 1,516 heart-surgery patients given high-dose fish oil around surgery, major bleeding was not higher than with placebo and fewer units of blood were transfused; the trial did not report results for people taking rivaroxaban. Tell your prescriber what omega-3 products and amounts you take, and ask before starting prescription-strength doses.

GinkgoLow

Ginkgo has mild antiplatelet activity, so the pair was thought to raise bleeding risk. In a study of 41 healthy adults, 240 mg of a standardized ginkgo extract (EGb 761), as a single dose or for 8 days, did not change rivaroxaban levels or its anti-factor Xa effect and caused no bleeding events. Results may differ for other ginkgo products or for people with other bleeding risks, so tell your prescriber or pharmacist before combining them.

Chia seedsLow

Chia contains plant omega-3 and fiber. In a 12-week trial in 20 adults with type 2 diabetes, about 37 g of chia a day lowered von Willebrand factor, a clotting protein, without changing blood-clotting safety tests; no study has tested chia with rivaroxaban. Treat chia as a normal food, keep intake steady, and mention a daily chia habit to your doctor or pharmacist.

Documented interactions

Evidence-graded pair pages with sources, dosing notes, and timing guidance, a complement to the narrative section above.

See all 3 Rivaroxaban interactions →

Choosing a product

What to look for on the label, and what to be skeptical of.

Look for…

Xarelto or generic rivaroxaban dispensed by a licensed pharmacy on your own prescription
The tablet strength on your label (2.5, 10, 15 or 20 mg) and whether it should be taken with food
A Medication Guide with each fill, which explains the bleeding and stopping-early warnings
Your pharmacy's interaction check against your other prescriptions and over-the-counter medicines

Be skeptical of…

"Natural blood thinner" supplements (high-dose vitamin E, fish oil, ginkgo, garlic or turmeric) presented as a replacement for an anticoagulant
Supplements marketed as safe with blood thinners without any evidence
Advice to stop or pause rivaroxaban on your own before dental work or surgery
Online sellers offering rivaroxaban without a prescription

Frequently asked questions

Can I take vitamin E with rivaroxaban?⌄

This page rates high-dose vitamin E supplements a high-severity interaction. Vitamin E can make platelets less sticky, and higher vitamin E levels were linked to more bleeding in an observational study of people taking warfarin-type blood thinners; whether this applies to rivaroxaban is not known. Ask your prescriber before starting a vitamin E supplement. Vitamin E from food is not the concern.

Is fish oil safe with rivaroxaban?⌄

This page rates it low severity. A large trial found high-dose fish oil did not increase bleeding around heart surgery, though the trial did not report results for people taking rivaroxaban. Tell your prescriber the omega-3 products and amounts you take, and ask before prescription-strength doses.

Can I take ginkgo with rivaroxaban?⌄

In a study of 41 healthy adults, a standardized ginkgo extract did not change rivaroxaban levels or its blood-thinning effect. This page rates it low severity, but other products and people with other bleeding risks may differ, so check with your prescriber or pharmacist first.

Do I need to avoid vitamin K foods like leafy greens?⌄

Not the way people on warfarin are told to. Rivaroxaban blocks factor Xa directly instead of working through vitamin K, and the label notes that even vitamin K given as a medicine is not expected to change its effect. Ask your prescriber if you have questions about your diet.

Can I take ibuprofen with rivaroxaban?⌄

The label says NSAIDs such as ibuprofen and naproxen, aspirin and other blood thinners increase bleeding risk with rivaroxaban. Ask your pharmacist or prescriber before using any over-the-counter pain reliever.

What if I miss a dose of rivaroxaban?⌄

It depends on your schedule. On once-daily dosing, the label says to take the missed dose right away and never to take two doses in the same day to make up for it. On 15 mg twice daily, take it right away so you get 30 mg that day. On 2.5 mg twice daily, skip it and take the next dose on time. Never stop on your own.

References by claim

stroke prevention in atrial fibrillation

Patel et al., 2011 · PubMed (2011) link

treatment of deep vein thrombosis and pulmonary embolism

Bauersachs et al., 2010 · PubMed (2010) link

Büller et al., 2012 · PubMed (2012) link

coronary and peripheral artery disease (with aspirin)

Eikelboom et al., 2017 · PubMed (2017) link

Safety

Xarelto (rivaroxaban) prescribing information · DailyMed (FDA label) link

Interaction: Vitamin E (high-dose supplements)

Pastori et al., 2013 · PMC (2013) link

Interaction: Fish oil (omega-3)

Akintoye et al., 2018 · PMC (2018) link

Interaction: Ginkgo

Hoerr et al., 2022 · PMC (2022) link

Interaction: Chia seeds

Vuksan et al., 2007 · PubMed (2007) link

Interaction: St. John's wort

Scholz et al., 2021 · PubMed (2021) link

Huppertz et al., 2018 · PMC (2018) link

Imai et al., 2008 · PMC (2008) link

Track Rivaroxaban with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora app.

Evidence-based·Updated Nov 16, 2026·Evidence current as of Nov 16, 2026·How we grade evidence

Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.